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Received February 12, 2014; accepted June 27, 2014AbstractBackground: Endoscopic sphincterotomy (ES) is an established treatment for patients with choledocholithiasis or common bile duct stones
(CBDS), but further management of patients after ES with recurrent CBDS remains controversial. Endoscopic papillary large balloon dilation
(EPLBD) has been used safely and effectively for stone removal in patients after ES with recurrent CBDS. The aim of this study was to evaluate
the clinical efficacy of EPLBD in patients after complete ES with recurrent CBDS.
Methods: Records of 891 patients with CBDS after complete ES from January 1991 to December 2008 were reviewed. Of 133 patients with
recurrent CBDS, 122 had complete endoscopic bile duct clearance. Twenty-three patients (Group 1) underwent EPLBD and 99 (Group 2)
underwent stone extraction without dilatation. Basic demographics and endoscopic findings at the first recurrence were recorded and analyzed.
The primary end point was the second CBDS recurrence.
Results: No statistical differences were observed between the two groups, except for larger CBDS size in Group 1. The bile duct clearance rate
was 96% in Group 1 and 91% in Group 2. No complications such as pancreatitis, perforation, and bleeding were noted in Group 1, and one
patient in Group 2 suffered from bleeding after stone extraction. The rate of second recurrent CBDS after endoscopic clearance for the first
recurrent CBDS was 17% in Group 1 and 60% in Group 2 ( p < 0.001). There were two independent factors for the second recurrence, including
cirrhosis (odds ratio 4.734, p ¼ 0.023) and stone extraction directly without major papilla expansion (odds ratio 6.050, p ¼ 0.003).
Conclusion: EPLBD is a safe and effective endoscopic treatment for recurrent CBDS in patients after ES. It can also facilitate complete
clearance of CBDS and prevent further CBDS recurrence.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Endoscopic sphincterotomy (ES) is a widely used method
of treatment for patients with choledocholithiasis or common
bile duct stones (CBDS).1 The actual ES procedure is tech-
nically demanding and associated with about 9.8% compli-
cations.2 Most complications are primarily related to the
indications for the procedure and the endoscopic technique.2
Endoscopic papillary balloon dilatation (EPBD), which wasociation. All rights reserved.
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for removing bile duct stones. It is more easily accessed and
less technically demanding than ES. It also causes less hem-
orrhage and less perforation, and can preserve the sphincter of
Oddi function.4,5 However, EPBD is not widely used due to its
associated higher risk of pancreatitis and a higher rate of using
mechanical lithotripsy, as reported in some studies.6 Endo-
scopic papillary large balloon dilation (EPLBD) after limited
ES, which was introduced by Ersoz et al,7 is effective in
removing bile duct stones and has an acceptable complication
rate.8 Recent studies have shown that EPLBD alone is a safe
and effective method for removing bile duct stones, and the
procedure is also technically easy to navigate.9,10
Patients after ES still have the risk of recurrent CBDS, with
the rate ranging from 4% to 24% over the duration of long-
term follow-up.11e14 There has been no consensus for the
management of patients with recurrent CBDS after prior ES.
Although most of the recurrent stones in Chinese patients are
loose bilirubinate stones,15 stone extraction is sometimes
difficult, especially in patients with multiple large stones and/
or papillary stenosis, even using a mechanical lithotripter. Data
on the repeated use of ES for extending the previous sphinc-
terotomy in these patients are limited and controversial. Some
studies suggested that EPLBD could be used safely in these
patients, with effective results.16e18
The aim of our study was to retrospectively evaluate the
long-term clinical efficacy of EPLBD compared with direct
stone extraction without balloon dilation in patients with
recurrent CBDS after prior ES.
2. Methods2.1. PatientsThis study has been approved by the Institutional Review
Board of Kaohsiung Veterans General Hospital (VGHKS12-
CT7-02).
Consecutive patients with recurrent CBDS after complete
ES in Kaohsiung General Veterans Hospital, Taiwan, from
January 1991 to December 2008 were reviewed. Patients with
previous biliary surgery, those with pancreatic or biliary ma-
lignant disorders, and pregnant women were excluded. We
recorded the basic demographics and endoscopic findings at
the first recurrence. Next, we divided the patients into two
groups (Groups 1 and 2) according to the endoscopic man-
agement approach for the recurrent CBDS.2.2. ProceduresThe preparation included local anesthesia of the pharynx
using 10% xylocaine, and intramuscular injection with 40 mg
hyoscine-N-butylbromide and 25e50 mg meperidine. Endo-
scopic retrograde cholangiopancreatography (ERCP) was
performed in the standard manner using a side-view endoscope
(JF-240; Olympus Optical Corporation, Tokyo, Japan). After
selective cannulation of the common bile duct using the cath-
eter, cholangiography was performed to confirm the diagnosisof recurrent CBDS. For Group 1 patients, a 0.035-inch guide-
wire (Boston Scientific Corp., Marlborough, MA, USA) was
then inserted into the bile duct through the catheter. EPLBD
was performed by passing a dilating balloon (CRE balloon
5.5 cm in length and 1.0e1.2 cm/1.2e1.5 cm/1.5e2.0 cm
in diameter; Boston Scientific Corp., MA, USA) via the
prepositioned guidewire into the bile duct using fluoroscopic
and endoscopic guidance. The balloon was inflated up to the
optimal size (10 mm in diameter) for 1e5 minutes according
to the patients' condition and tolerance. In order to minimize
the risk of perforation, the size of the balloon should not exceed
the largest diameter of the CBD, and further expansion of
balloon was avoided once the patient felt intolerable pain. After
removal of the balloon and guidewire, the CBDS were removed
using a Dormia basket or balloon-tipped catheter, with or
without the aid of mechanical lithotripsy. A mechanical litho-
tripter (BML-4Q; Olympus Optical, Tokyo, Japan) was used to
fragment the stones if the maximal stone diameter was larger
than the diameter of the distal bile duct or the stones could not
be removed using the Dormia basket or balloon-tipped catheter.
The decision to use balloon dilation was made depending on
the endoscopists' personal experiences. For Group 2 patients,
direct stone extraction was performed after cholangiogram
without balloon dilatation. A second attempt at stone extraction
was performed within 7 days for incomplete removal of stones
in the first treatment session. All patients were observed in the
hospital for at least 24 hours after endoscopic treatment.
Procedure-related adverse events and incidents were recorded
according to the definitions and grading systems of the recent
workshop held by the American Society of Gastrointestinal
Endoscopy.19 During the ERCP procedure, dimensions of the
juxtapapillary diverticulum and CBD as well as size and
number of stones were recorded. Stone removal was declared
complete if the final cholangiogram showed no residual stones.
Clinical evaluation of symptoms and serum amylase was per-
formed the following day.2.3. Follow upPatients with complete clearance of the bile duct were
assigned to regular follow-up after discharge at a special clinic.
We followed up the patients every 2 weeks until normalization
of liver function tests, and every 3 months thereafter. During
each visit, a blood sample was taken routinely for liver function
tests, including total serum bilirubin, albumin, alanine amino-
transferase, aspartate aminotransferase, and alkaline phospha-
tase. Abdominal ultrasound was suggested every 6e12 months,
or when abnormal liver function test results or clinical symp-
toms suggested CBDS recurrence. Endoscopic retrograde
cholangiography was performed if recurrent biliary symptoms,
abnormal liver function tests, or sonography suggested recurrent
CBDS. When repeated endoscopic retrograde cholangiography
confirmed the diagnosis of recurrent CBDS, endoscopic
removal of stones (with or without further balloon dilation) was
performed simultaneously in the same session, or the patient
was referred to a surgeon. Telephone contact was made with
patients who were unable to return to the hospital.
Table 2
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Outcomes of two groups of patients after endoscopic treatment.
Group 1 Group 2 p
Complication 0 1% (1/99) > 0.99
Complete bile duct clearance 96% (23/24) 91% (99/109) 0.688
Complete clearance in one session 87% (20/23) 80% (79/99) 0.561
Lithotripsy 13% (3/23) 7% (7/99) 0.397
Second recurrence of CBDS 17% (4/23) 60% (60/99) < 0.001
Interval between two recurrence (mo) 20 ± 22.9 24 ± 28.5 0.967
Follow-up time (mo) 95 ± 58.1 90 ± 45.3 0.761
CBDS ¼ common bile duct stones.All statistical analyses were performed with the SPSS
program (version 12.0.1C). The values were expressed as
mean ± standard deviation. Categorical variables were tested
by the chi-square test or using Fisher's exact test. Continuous
values were analyzed by ManneWhitney U test. Cumulative
re-recurrence was analyzed by the KaplaneMeier method and
log rank test. A p value of <0.05 was considered significant.
3. Results
Records of 891 patients with CBDS after complete ES in
Kaohsiung General Veterans Hospital from January 1991 to
December 2008 were reviewed. Of the 133 (14.9%) patients
having recurrent CBDS, 122 with complete bile duct clearance
for the recurrent CBDS were further divided into two groups
according to the endoscopic procedure: 23 patients underwent
EPLBD (Group 1) and 99 stone extraction without dilatation
or expansion of previous sphincterotomy (Group 2). Basic
demographics and endoscopic findings at the first recurrence
were recorded (Table 1), and no statistical difference was
observed in age, sex, concomitant systemic disease, gall-
bladder status, previous ES length, common bile duct size,
juxtapapillary diverticulum, and lithotripsy between the two
groups. However, a larger CBD stone size was noted in Group
1, where p ¼ 0.024 using the Chi-square test.
The complete bile duct clearance rate was 96% (23/24) in
Group 1 and 91% (99/109) in Group 2 (Table 2). A total of 11
patients had incomplete clearance of bile duct, one in Group 1
and 10 in Group 2. Of the failed patients in Group 2, four
received subsequent biliary stent insertion, four received sur-
gical intervention, one underwent nasobiliary drainage withTable 1
Basic demographics and endoscopic findings.
Group 1 (n ¼ 24) Group 2 (n ¼ 109) p
Sex (male) 67% (16/24) 65% (71/109) 0.887
Age (y) 64.3 ± 10.17 66.6 ± 10.12 0.224a
Juxtapapillary diverticulum 46% (11/24) 56% (61/109) 0.367
Diabetes mellitus 4% (1/24) 13% (14/109) 0.305
Hypertension 21% (5/24) 29% (32/109) 0.399
Cirrhosis 4% (1/24) 17% (19/109) 0.123
Stone size (cm) 1.7 ± 0.79 1.4 ± 0.70 0.854a
1.5 13 24 0.024b,*
<1.5 9 50
Multiple stones 63% (15/24) 71% (77/109) 0.434
CBD size (cm) 1.9 ± 0.67 1.9 ± 0.63 0.524a
1.5 19 76 0.595b
<1.5 4 22
Balloon size (cm) 1.5 ± 0.42 d
Intact gallbladder 42% (10/24) 27% (29/109) 0.142
Gallstones 29% (7/24) 16% (17/109) 0.143
s/p Billroth-II anastomosis 0% (0/24) 3% (3/109) > 0.99
Intrahepatic duct stones 17% (4/24) 20% (22/109) > 0.99
*p < 0.05.
CBD ¼ common bile duct; EPLBD ¼ endoscopic papillary large balloon
dilation; ES ¼ endoscopic sphincterotomy.
a Analyzed using the ManneWhitney U test.
b Analyzed using the Chi-square test.subsequent mortality due to sepsis, and one refused further
management. Of the four patients receiving salvage stent
insertion, two had subsequent surgical intervention, one was
lost to follow up, and the last patient refused further man-
agement and expired due to sepsis 6 months after the stent
insertion. The only patient with incomplete clearance of bile
duct after EPLBD had a poor tolerance for the procedure and
refused further management. The family asked to transfer the
patient to another hospital, who was then lost to further follow
up.
Most patients received only one session of endoscopic
treatment (87% in Group 1 and 80% in Group 2, p ¼ 0.561)
for achieving complete bile duct clearance. The use of me-
chanical lithotripter showed no statistically significant differ-
ence between the two groups (13% in Group 1, 7% in Group 2,
p ¼ 0.397). No complications, including pancreatitis, perfo-
ration, and bleeding, were noted in Group 1. One patient in
Group 2 suffered from intraprocedural bleeding after stone
extraction, and bleeding was controlled by endoscopic
injection.
Patients of Group 1 had a significantly lower rate of second
recurrent CBDS than patients of Group 2 [17% (4/23) vs. 60%
(60/99), p < 0.001, Table 2]. In KaplaneMeier analysis,
Group 1 patients had a significantly lower incidence of re-
recurrent CBDS (Fig. 1, p ¼ 0.0017). The interval between
two recurrences in these two groups showed no statistical
difference (20 months vs. 24 months, p ¼ 0.745). The overall
follow-up durations in both groups were also similar, as can be
noted from Table 2.
Among the potential risk factors for recurrent CBDS,
cirrhosis (odds ratio 4.734, 95% confidence interval
1.236e18.138, p¼ 0.023) and stone extraction directly without
major papilla expansion (odds ratio 6.050, 95% confidence
interval 1.880e19.469, p ¼ 0.003) were two independent fac-
tors for the re-recurrence, as shown in Tables 3 and 4.
4. Discussion
Once the patients after ES had recurrent CBDS, the like-
lihood of a second recurrence was reportedly as high as 33%.20
Although loss of the function of sphincter may cause
ascending cholangitis in complete ES or papillary stenosis
(0.5e3.9%),21 bile stasis may also be an important factor
contributing to the recurrence of bile duct stones. Further
management of recurrent stones in patients after ES remains
Fig. 1. Cumulative re-recurrence rate of common bile duct stones in both
groups. EPLBD ¼ endoscopic papillary large balloon dilation;
ERCP ¼ endoscopic retrograde cholangiopancreatography.
Table 3
Univariate analysis of risk factors for re-recurrent common bile duct stones.
Re-recurrencea Nonrecurrencea p
Sex
Male/female 44/18 35/25 0.144
Age (y)
65/<65 42/20 35/25 0.282
Hypertension
Yes/no 18/44 16/44 0.771
Type 2 DM
Yes/no 8/54 6/54 0.615
Cirrhosis
Yes/no 14/48 3/57 0.005*
JPD
Yes/no 31/31 36/24 0.267
Gallstone
Yes/no 22/40 22/40 0.803
Lithotripter
Yes/no 5/57 5/55 > 0.99
Stone number
2/single 42/20 42/18 0.788
Stone size (cm)
1.5/<1.5 20/28 17/31 0.529
CBD size (cm)
1.5/<1.5 49/13 46/13 0.887
Endoscopic management
EPLBD/ERCP 4/58 19/41 <0.001*
*p < 0.05.
CBD ¼ common bile duct; DM ¼ diabetes mellitus; EPLBD ¼ endoscopic
papillary large balloon dilation; ERCP ¼ endoscopic retrograde chol-
angiopancreatography; JPD ¼ juxtapapillary diverticulum.
a Number of patients.
Table 4
Multivariate analysis of the risk factors for recurrent common bile duct stones.
OR 95% CI p
Cirrhosis 4.734 1.236e18.138 0.023
Endoscopic management without EPLBD 6.050 1.880e19.469 0.003
CI ¼ confidence interval; ERCP ¼ endoscopic retrograde chol-
angiopancreatography; OR ¼ odds ratio.
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sometimes technically difficult and associated with the risks of
perforation and hemorrhage.22,23 EPLBD is a good alternative
procedure because it can re-expand the papilla with safety and
effectiveness. It can also treat papillary stenosis and lower bile
duct stricture simultaneously.
In this study, Group 1 patients who underwent EPLBD had
a significantly lower second recurrence of CBD stones (17%
vs. 60%, p < 0.001). The literature has mentioned ES, juxta-
papillary diverticulum, intact gallbladder with stones in situ, a
large CBD diameter (>15 mm), CBD angulation, biliary
stricture, papillary stenosis, and lithotripsy as possible risk
factors for recurrent CBD stones.24e29 Our previous study
reported that 86% of recurrent bile duct stones were bilir-
ubinate stones, and only 7% were pure cholesterol stones.15
Sugiyama and Atomi30 and Cetta31 found that all recurrent
stones were pigment stones, and suggested that bile stasis and
bacterial infection might contribute to the recurrent stone
formation. Most of the recurrent bilirubinate stones were loose
in consistency. The conventional basket could easily to break
the stones into multiple pieces, especially if the biliary outlet
is not big enough for removal of the entire stone. Ten cases (3
in Group 1 and 7 in Group 2) received lithotripsy for stone
fragmentation. The retained small stone fragments may
become the nidus for recurrent stone growth. Therefore, by
enlarging the biliary outlet, EPLBD may play an important
role in biliary emptying and prevent recurrent CBDS.
Cirrhosis was another independent risk factor for the re-
recurrent CBDS. In our previous study, we also described
that cirrhosis was an independent factor for long-term biliary
complication.24 Delayed biliary emptying with prolonged Tmax
(time required for maximal hepatic activity) and T1/2max (timerequired for peak activity to decrease by 50%) was noted in
liver fibrosis and cirrhosis patients, as assessed by 99mTc-
mebrofenin cholescintigraphy, compared to normal control.32
Bile stasis may further contribute to recurrent chol-
edocholithiasis formation.33 We do not perform cholescintig-
raphy in our patients, and further prospective study is needed.
It is sometimes difficult to enlarge the papillary orifice
further after previous complete sphincterotomy, particularly in
patients with a large juxtapapillary diverticulum (46e56% in
our series). Although Sugiyama et al,20 Sugiyama and
Atomi,30 and Mavrogiannis et al23 found repeated ES as safe
as initial ES (complication rate 2e2.46% in repeated ES),
Goodall34 reported an increase in bleeding risk after repeated
ES (1st ES, 8.2%; 2nd ES, 16.1%; and 3rd ES, 60%). In Elmi
and Silverman's35 retrospective study, 80 patients after ES and
stone clearance were enrolled. Of them, 13 patients suffered
from papillary stenosis and underwent repeated ES and three
suffered from complications without mortality: one mild
pancreatitis, one severe bleeding, and one severe duodenal
60 T.-J. Tsai et al. / Journal of the Chinese Medical Association 78 (2015) 56e61perforation. Leung et al22 found that 42.3% of patients suf-
fered from bleeding after extension of previous sphincter-
otomy and showed that it was one of the independent risk
factors for ES-induced bleeding. The safety of repeated ES
was still in doubt. In our retrospective analysis, no patients
underwent repeated ES or EPLBD after limited ES, the reason
for which might be attributed to endoscopists' experiences and
decision.
EPBD alone, EPLBD alone, and EPLBD after limited ES
are the current balloon-based methods for CBDS management.
Conventional EPBD using an 8-mm balloon was reported to
be associated with a higher risk of pancreatitis and more
frequent use of mechanical lithotripsy.6 A recent meta-analysis
by Liao et al36 showed that the ballooning time of EPBD was
inversely associated with pancreatitis risk, and EPBD with
adequate ballooning time may be preferred to ES. EPLBD
alone was also reported to be safe and effective for the removal
of CBDS with innate papillary orifice in our medical center.10
In this study, EPLBD seemed to be a good substitute for
enlargement of papillary orifice from previous ES with safe
and effective outcome. The large opening of the major papilla
was enlarged after EPLBD and might allow complete retrieval
of most of the stones without the need of crushing them, thus
avoiding further nidus formation. EPLBD was easy to perform
without early complications, and the re-recurrent rate was
markedly decreased (17% vs. 60%, p < 0.001). In our previous
study, we found that poor biliary emptying is a risk factor for
recurrent CBD stones.33 This was probably because the distal
bile duct and whole biliary sphincter were dilated and des-
tructed simultaneously, thus facilitating bile drainage and
smooth passage of residual stone fragments or newly formed
small stone particles.
The pathogenesis of ampullary stenosis is not well docu-
mented. Repeated coagulation, multiple interventions, ten-
dency to develop excessive fibrotic reaction, bleeding, and
postendoscopic hemostasis were the possible causes of
ampullary stenosis.21 Papillary stenosis is divided into two
subtypes: type I means the stenosis is confined in the intra-
duodenal part of the sphincter, and type II means the stenosis
extends into the common bile duct.21 In type II lesions, repeated
sphincterotomy is not helpful, and balloon-based methods seem
to be more effective. In addition, repeated sphincterotomy for
treatment of papillary stenosis may result in a higher compli-
cation rate (16e23%).21,35 In patients undergoing EPBD, no
papillary stenosis was reported after 16 months of follow-up.37
Additionally, EPLBD seems to be more effective and is asso-
ciated with a lower rate of occurrence of papillary stenosis.
However, these long-term effects need further investigation.
The limitation of our study was retrospective, and patients
receiving EPLBD had a typically larger stone(s) than the pa-
tients in Group 2. A large stone size is one of the risk factors
for recurrent CBD stone.38 Although patients in the EPLBD
group had a larger stone size, the recurrence rate decreased
after the endoscopic treatment.
Otherwise, the comparatively small number of patients who
underwent EPLBD (23 vs. 99 patients) was also noted. This
might be one of the biases responsible for the lower recurrencerate in the EPLBD group. Most recurrent CBDS patients un-
derwent ERCP alone prior to 2003 and EPLBD after 2003.
Selection of EPLBD as the endoscopic treatment was made
depending on the personal experiences of the endoscopists.
However, which condition is needed for re-expansion of the
previous sphincterotomy? Should we routinely performEPLBD
on patients with recurrent CBDS, or only on patients with
papillary stenosis, or those with large multiple recurrent stones
and relative stricture of the distal common bile duct? These
questions need further prospective research and exploration.
In conclusion, EPLBD for patients with recurrent bile duct
stones after complete ES is a safe and effective treatment
method. It can also facilitate complete clearance of CBDS and
prevent further recurrence of CBDS.References
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